ClinicalTrials.gg
RecruitingNCT07947745Ultra- HEROUpdated Nov 19, 2026

Ultra-hypofractionated radiotHErapy and Concomitant Oral RelugOlix for Treatment of Intermediate Risk Prostate Cancer.

An interventional study of Ultrahypofractionated RT+Relugolix in Prostate Cancer (Adenocarcinoma), sponsored by Azienda Ospedaliero-Universitaria Careggi. Recruiting at 1 site in Italy. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Azienda Ospedaliero-Universitaria Careggi · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
73
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 339 studies in Prostatic Neoplasms with a site in Italy — 94 open to participants now, 143 under way, 36 of them phase 3. Prostatic Neoplasms · Italy.

Planned enrollment
195th of 244
73 · median 220
Started
2025
with 30 others
No phase
57 of 339
20 open now
Primary completion
2027-06
later than 79 of 142 live
Registered
304th of 339
by date

Among the 339 studies in Prostatic Neoplasms with a site in Italy, this one is the 195th largest by planned enrollment of the 244 interventional ones that give a count, is one of 31 that started in 2025, is one of 57 with no phase, reaches primary completion later than 79 of the 142 other live ones, and was the 304th registered.

Prostatic Neoplasms

7,055 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

94 of the 339 studies in Prostatic Neoplasms with a site in Italy are open now. Recruiting first, the newest first:

89 more — sign in →

All 94 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 339 studies in Prostatic Neoplasms with a site in Italy, or all of them as a file.
02

Study summary

Prospective evidence is needed in order to assess if concomitant treatment with short course ADT with relugolix and RT may obtain the same disease control benefit if compared to historical data related to standard ADT with LH- RH analogues. With this purpose, we designed an interventional trial aimed to evaluate rate of complete biochemical response in an homogeneous cohort of patients affected by intermediate risk localized prostate cancer undergoing prostate radiotherapy+short course oral relugolix.

Read the detailed description

This is a Prospective, no-profit, single arm phase II, interventional multicentric trial aimed to evaluate the effectiveness of concomitant prostate RT and short course oral Relugolix if compared to literature data related to standard prostate RT associated with standard ADT.

03

Conditions studied

  • Prostate Cancer (Adenocarcinoma)

Keywords

  • prostate cancer
  • Ultrahypofractionated Radiotherapy
  • Relugolix
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years old -Signed -Hystological confirmation of prostate adenocarcinoma -Deemed suitable for ultrahypofractionated treatment on prostate (IPSS \< 15, prostate volume \<90 cc)
  • Patients should be candidate to androgen deprivation therapy for the management of prostate cancer
  • Unfavourable intermediate risk (GLeason 4+3 and or >50% of cores positive and or > 2 intermediate risk factor)

Exclusion criteria

Exclusion Criteria:

  • disease at diagnosis
  • Any high-risk feature (Gleason >4+3, >cT3a, PSA > 20 ng/ml)
  • Any contrahindication for ultrahypofractionated radiotherapy on prostate
  • Participants with myocardial infarction, unstable symptomatic ischemic heart disease, cerebrovascular events, or any significant cardiac condition within the prior 6 months.
  • Active conduction system abnormalities.
  • Uncontrolled hypertension.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
73 participants (estimated)

Study arms

  • Experimental
    Intervention

    Patients will be treated with ultrahypofractionated prostate radiotherapy for a total dose of 36.25 Gy in 5 fractions, 7.25 Gy each, every other day. Concomitant treatment with oral Relugolix will be administered.

    Other: Ultrahypofractionated RT+Relugolix

Interventions

  • OtherUltrahypofractionated RT+Relugolix

    Patients will be treated with ultrahypofractionated prostate radiotherapy for a total dose of 36.25 Gy in 5 fractions, 7.25 Gy each, every other day. Concomitant treatment with oral Relugolix will be administered.

06

What researchers measure

Primary outcomes

  1. Biochemical response

    To assess rate of complete biochemical response after 6 months of treatment, defined as PSA \<0.5 ng/ml

    Time frame: 6 months from the last patient enrollment

Secondary outcomes

  1. Biochemical relapse free survival (BRFS) at 2 years

    Biochemical relapse free survival (BRFS) at 2 years after end of radiotherapy. Biochemical relapse will be defined as a rise by 2 ng/mL or more above the nadir PSA according to RTOG- ASTRO Phoenix Consensus Conferenc

    Time frame: 2 years after last patient enrollment

  2. testosterone recovery at 90 days from the end of ADT treatment

    Rate of patients with testosterone recovery at 90 days from the end of ADT treatment

    Time frame: 90 days from the last patient enrollment

  3. Non pathological fracture at 2 years

    Rate of patients experiencing non pathological fracture at 2 years

    Time frame: 2 years after last patient enrollment

  4. cardiovascular events at 48 weeks (myocardial infarction and stroke)

    Rate of cardiovascular events at 48 weeks (myocardial infarction and stroke)

    Time frame: 48 weeks after last patient enrollment

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Rosen RC, Allen KR, Ni X, Araujo AB. Minimal clinically important differences in the erectile function domain of the International Index of Erectile Function scale. Eur Urol. 2011 Nov;60(5):1010-6. doi: 10.1016/j.eururo.2011.07.053. Epub 2011 Jul 30. PubMed 21855209 ↗
  • D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008 Jan 23;299(3):289-95. doi: 10.1001/jama.299.3.289. PubMed 18212313 ↗
  • Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74. doi: 10.1016/j.ijrobp.2006.04.029. PubMed 16798415 ↗
  • van As N, Griffin C, Tree A, Patel J, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Camilleri P, Kancherla K, Frew J, Chan A, Naismith O, Armstrong J, Staffurth J, Martin A, Dayes I, Wells P, Price D, Williamson E, Pugh J, Manning G, Brown S, Burnett S, Hall E. Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer. N Engl J Med. 2024 Oct 17;391(15):1413-1425. doi: 10.1056/NEJMoa2403365. PubMed 39413377 ↗
  • Widmark A, Gunnlaugsson A, Beckman L, Thellenberg-Karlsson C, Hoyer M, Lagerlund M, Kindblom J, Ginman C, Johansson B, Bjornlinger K, Seke M, Agrup M, Fransson P, Tavelin B, Norman D, Zackrisson B, Anderson H, Kjellen E, Franzen L, Nilsson P. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019 Aug 3;394(10196):385-395. doi: 10.1016/S0140-6736(19)31131-6. Epub 2019 Jun 18. PubMed 31227373 ↗
  • D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004 Aug 18;292(7):821-7. doi: 10.1001/jama.292.7.821. PubMed 15315996 ↗
  • Kishan AU, Sun Y, Hartman H, Pisansky TM, Bolla M, Neven A, Steigler A, Denham JW, Feng FY, Zapatero A, Armstrong JG, Nabid A, Carrier N, Souhami L, Dunne MT, Efstathiou JA, Sandler HM, Guerrero A, Joseph D, Maingon P, de Reijke TM, Maldonado X, Ma TM, Romero T, Wang X, Rettig MB, Reiter RE, Zaorsky NG, Steinberg ML, Nickols NG, Jia AY, Garcia JA, Spratt DE; MARCAP Consortium group. Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis. Lancet Oncol. 2022 Feb;23(2):304-316. doi: 10.1016/S1470-2045(21)00705-1. Epub 2022 Jan 17. PubMed 35051385 ↗
  • Jones CU, Pugh SL, Sandler HM, Chetner MP, Amin MB, Bruner DW, Zietman AL, Den RB, Leibenhaut MH, Longo JM, Bahary JP, Rosenthal SA, Souhami L, Michalski JM, Hartford AC, Amin PP, Roach M 3rd, Yee D, Efstathiou JA, Rodgers JP, Feng FY, Shipley WU. Adding Short-Term Androgen Deprivation Therapy to Radiation Therapy in Men With Localized Prostate Cancer: Long-Term Update of the NRG/RTOG 9408 Randomized Clinical Trial. Int J Radiat Oncol Biol Phys. 2022 Feb 1;112(2):294-303. doi: 10.1016/j.ijrobp.2021.08.031. Epub 2021 Sep 1. PubMed 34481017 ↗
  • Pisansky TM, Hunt D, Gomella LG, Amin MB, Balogh AG, Chinn DM, Seider MJ, Duclos M, Rosenthal SA, Bauman GS, Gore EM, Rotman MZ, Lukka HR, Shipley WU, Dignam JJ, Sandler HM. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol. 2015 Feb 1;33(4):332-9. doi: 10.1200/JCO.2014.58.0662. Epub 2014 Dec 22. PubMed 25534388 ↗
  • Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, Shipley WU. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol. 2008 May 20;26(15):2497-504. doi: 10.1200/JCO.2007.14.9021. Epub 2008 Apr 14. PubMed 18413638 ↗
  • Denham JW, Steigler A, Lamb DS, Joseph D, Turner S, Matthews J, Atkinson C, North J, Christie D, Spry NA, Tai KH, Wynne C, D'Este C. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol. 2011 May;12(5):451-9. doi: 10.1016/S1470-2045(11)70063-8. PubMed 21440505 ↗
  • Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Billiet I, Torecilla JL, Pfeffer R, Cutajar CL, Van der Kwast T, Collette L. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol. 2010 Nov;11(11):1066-73. doi: 10.1016/S1470-2045(10)70223-0. Epub 2010 Oct 7. PubMed 20933466 ↗
  • Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002 Jul 13;360(9327):103-6. doi: 10.1016/s0140-6736(02)09408-4. PubMed 12126818 ↗
  • Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B; HERO Study Investigators. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med. 2020 Jun 4;382(23):2187-2196. doi: 10.1056/NEJMoa2004325. Epub 2020 May 29. PubMed 32469183 ↗
  • Delgado J, Ory J, Loloi J, Deebel NA, Bernstein A, Nackeeran S, Zucker I, Ramasamy R. Persistent Testosterone Suppression After Cessation of Androgen Deprivation Therapy for Prostate Cancer. Cureus. 2022 Dec 19;14(12):e32699. doi: 10.7759/cureus.32699. eCollection 2022 Dec. PubMed 36686106 ↗
  • Nguyen PL, Alibhai SM, Basaria S, D'Amico AV, Kantoff PW, Keating NL, Penson DF, Rosario DJ, Tombal B, Smith MR. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015 May;67(5):825-36. doi: 10.1016/j.eururo.2014.07.010. Epub 2014 Aug 2. PubMed 25097095 ↗
  • Schmidt-Hegemann NS, Zamboglou C, Mason M, Mottet N, Hinnen K, De Meerleer G, Cozzarini C, Maingon P, Henry A, Spahn M, Cornford P, Belka C, Wiegel T. ESTRO-ACROP recommendations for evidence-based use of androgen deprivation therapy in combination with external-beam radiotherapy in prostate cancer. Radiother Oncol. 2023 Jun;183:109544. doi: 10.1016/j.radonc.2023.109544. Epub 2023 Feb 20. PubMed 36813168 ↗

Individual participant data

Plan to share: No — IPD will be maintained in a local data repository

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2027, 24 months after the start.

Of 1,100 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 86. This study's planned 24 months is below that.

Counting every sponsor, half of 1,158 studies reached it within 43 months; a quarter within 22 and three quarters within 84.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2025
First posted
Nov 19, 2026
StartActual
Jun 18, 2025
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 30, 2028
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947745
Lead sponsor
Azienda Ospedaliero-Universitaria Careggi
Responsible party
Lorenzo Livi (Prof. Lorenzo Livi, Azienda Ospedaliero-Universitaria Careggi) — Principal investigator
First posted
Nov 19, 2026
Start date
Jun 18, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 30, 2028 (estimated)
Last update
Nov 19, 2026

Study contacts

Lorenzo Livi, Full professor
Contact
rt.datamanager@sbsc.unifi.it
055 2751828 ext. +39

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion